ARCA biopharma’s stock nearly quadruples on COVID treatment news
WESTMINSTER — Arca biopharma Inc. (Nasdaq: ABIO) became the latest darling among health-care stocks Thursday after saying one of its drug candidates is showing promise as a treatment for blood clotting seen in some COVID-19 patients.
In a statement, the Westminster pharmaceutical company said it will begin development to see if its drug candidate AB201 could be used to reduce blood clots and inflammatory responses induced by the immune system for certain patients of the disease. The drug is being developed as an anti-clotting agent for heart attack patients, but clotting has also manifested in other highly…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Nextera Healthcare LLC and ImagineMD have combined to form a single direct-primary-care organization for employer…
-
LOVELAND — The Stinging Nettle has taken up residence in downtown, filling a hole recently…
-
Mindful Therapy Group of Colorado P.C., a national collaborative of mental health clinicians, will open…
-
OneOncology, a physician-led national platform for independent oncology practices, has acquired United Urology Group, a…
